Testosterone gels get black-box warnings

FDA is slapping black-box warnings on two testosterone products, AndroGel and Testim, aiming to alert patients to serious side effects among children inadvertently exposed to the gels. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.